Zentalis Pharmaceuticals financials
$2.72+4.42%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $67.4M | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $67.4M | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | 100.0% | — | — | — | — |
| Operating income | -$152.8M | -$191.2M | -$299.5M | -$227.3M | -$165.0M | -$118.8M |
| Net income | -$137.1M | -$165.8M | -$292.2M | -$236.8M | -$158.7M | -$117.8M |
| Net margin | — | −246.0% | — | — | — | — |
| Diluted EPS | $-1.91 | $-2.33 | $-4.47 | $-4.48 | $-3.72 | $-4.19 |
| EBITDA | -$144.3M | -$186.2M | -$298.1M | -$225.9M | -$216.0M | -$118.6M |
| Operating cash flow | -$125.2M | -$170.9M | -$207.8M | -$163.8M | -$154.1M | -$86.8M |
| Free cash flow | -$125.2M | -$171.1M | -$208.4M | -$166.3M | -$160.2M | -$87.6M |
| Diluted shares | 71.9M | 71.1M | 65.4M | 52.9M | 42.7M | 28.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $36.0M | $33.9M | $28.0M | $43.1M | $59.7M | $55.0M |
| Short-term investments | $209.9M | $337.2M | $454.9M | $394.3M | $280.2M | $283.6M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $289.0M | $430.3M | $551.7M | $539.3M | $454.5M | $365.6M |
| Total liabilities | $72.8M | $93.2M | $114.3M | $105.3M | $90.0M | $32.2M |
| Shareholders' equity | $216.2M | $337.2M | $437.4M | $434.0M | $364.5M | $333.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology